At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 515 enrolled
Drug / intervention
MD-7246 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-range-finding Study of MD-7246 Administered Orally for 12 Weeks to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome
In Brief
A Phase 2 clinical trial evaluating MD-7246 and Placebo for Irritable Bowel Syndrome With Diarrhea (IBS-D). Completed, enrolled 515 participants across 80 sites.
Detailed Summary
To evaluate the safety and tolerability, treatment effect on abdominal pain, and dose response of MD-7246 administered orally to patients with diarrhea-predominant irritable bowel syndrome (IBS-D).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsAllergan Sales, LLC
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedApr 2019
Enrollment StartMay 2019
Primary CompletionFeb 2020
Study CompletionMar 2020
TodayJul 2026
First PostedApr 30, 2019
Enrollment StartMay 1, 2019
Primary CompletionFeb 26, 2020
Study CompletionMar 11, 2020
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 7.2 years ago
Interventions
MD-7246drug
Oral tablet
Placebodrug
Matching oral tablet